What Is the 340B Program? A Complete Guide to Eligibility, Compliance, and Benefits for Covered Entities

22 May What Is the 340B Program? A Complete Guide to Eligibility, Compliance, and Benefits for Covered Entities

The 340B Drug Pricing Program is a federal policy aimed at helping safety-net providers stretch their budgets so they can serve more patients in need. By allowing eligible organizations to buy outpatient medicines at reduced prices, the program frees up funds that can be reinvested in patient care, outreach, and clinical services. This guide explains who qualifies, how the program operates, key compliance expectations, and the financial effects covered entities can expect. Knowing these elements is essential for organizations that want to participate responsibly and maximize the program’s value.

For background on the program’s original intent and how it functions in practice, consider this summary perspective.

Understanding the 340B Drug Pricing Program: Purpose and Benefits

The 340B Drug Pricing Program, established by the Veterans Health Care Act of 1992, was created to expand access to outpatient medications for low‑income and uninsured patients. It enables qualified hospitals and other covered entities to purchase certain outpatient drugs at substantially discounted prices from manufacturers. These entities may then receive standard reimbursement from public and private payers when they dispense and administer these medications. The federal goal is for 340B to help covered entities “stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.”

The unintended consequences of the 340B safety‐net drug discount program, S Thomas, 2020

Below we unpack the program’s requirements and operations, answer common questions about eligibility and audits, and summarize recent regulatory developments. This information is intended to help covered entities make informed decisions about participation and compliance.

What Are the Eligibility Requirements for Covered Entities in the 340B Program?

Participation in 340B requires meeting specific eligibility standards set by the Health Resources and Services Administration (HRSA). Those standards are designed to direct discounted drug pricing to providers that serve large shares of low‑income, uninsured, or underinsured patients.

Which Organizations Qualify as Covered Entities Under the 340B Program?

Covered entities include several types of safety‑net and public providers, such as:

1. Disproportionate Share Hospitals (DSH): Hospitals that treat a high volume of low‑income patients.
2. Federally Qualified Health Centers (FQHCs): Community clinics that provide care regardless of patients’ ability to pay.
3. Ryan White HIV/AIDS Program Grantees: Providers delivering services to people living with HIV/AIDS.
4. State‑operated AIDS Drug Assistance Programs (ADAPs): Programs that supply medications to low‑income individuals with HIV/AIDS.

Each organization must document that it meets HRSA’s eligibility rules to enroll and remain in the program.

How Does HRSA Define Eligibility Criteria for Safety-Net and Public Sector Providers?

HRSA evaluates eligibility based on an entity’s mission, patient mix, and the extent to which it provides care regardless of a patient’s ability to pay. Key factors include the percentage of uninsured or underinsured patients and the organization’s demonstrated commitment to serving vulnerable populations. Falling short of these expectations can jeopardize 340B status, so ongoing compliance with HRSA criteria is essential.

How Does the 340B Drug Pricing Program Work for Covered Entities?

The 340B Program lets eligible providers buy certain outpatient drugs at manufacturer-negotiated discounts, creating savings on drug acquisition. Those savings can be used to support a range of patient services and organizational needs.

What Discounts and Drug Pricing Benefits Does the 340B Program Provide?

Discounts under 340B vary but often fall between roughly 20% and 50% off retail pricing, depending on the drug and manufacturer agreements. Covered entities can redirect those savings toward expanding clinical programs, improving access, or covering services that are otherwise underfunded. For many safety‑net providers, the financial impact is material and supports broader care delivery goals.

For analysis of the program’s financial and community impacts, see this comparative study of participating and non‑participating hospitals.

340B Program: Expanding Access and Financial Outcomes for Safety-Net Hospitals

Abstract: The 340B Drug Pricing Program was designed to increase access to care for low‑income and uninsured patients by enabling safety‑net hospitals and clinics to purchase outpatient drugs at reduced prices. Over time the program’s scope has grown, prompting analysis of whether participating hospitals deliver the intended community benefits. Using recent hospital financial data, researchers compared charity care, Medicaid admissions, uncompensated care, and costs related to uninsured patients across 340B and non‑340B hospitals, with subgroup analysis for DSH, CAH, RRC, SCH, and NCI‑designated hospitals.

Financial Outcomes and Community Benefit in the 340B Program: Comparing 340B and Non-340

B Hospitals, R Popovian, 2026

How Do Contract Pharmacies Participate in the 340B Program?

Contract pharmacies extend access by allowing covered entities to dispense 340B‑purchased medicines at retail locations. This model is especially useful where the covered entity does not operate its own pharmacy. Entities can contract with multiple pharmacies to broaden geographic reach and improve patient convenience, but these arrangements require careful oversight to remain compliant.

What Are the Compliance Requirements and Audit Best Practices for the 340B Program?

Maintaining 340B eligibility depends on rigorous compliance. Covered entities must follow HRSA guidance, keep clear records, and implement systems that prevent diversion and duplicate discounts.

How Should Covered Entities Prepare for 340B Program Compliance Audits?

Audit preparation typically includes:

1. Documentation: Keep accurate, auditable records of all 340B purchases and dispensing activity.
2. Training: Train staff on program rules, documentation standards, and pharmacy workflows.
3. Regular Reviews: Run internal audits and spot checks to find and fix issues before external review.

Proactive controls and clear processes reduce audit risk and demonstrate a culture of compliance.

What Are the Common Compliance Challenges and How to Address Them?

Typical compliance pain points include:

1. Record‑Keeping: High patient volumes and complex billing can make complete documentation difficult.
2. Understanding Regulations: The program’s technical rules are nuanced and change over time, which can lead to accidental non‑compliance.
3. Contract Pharmacy Management: Ensuring partner pharmacies follow 340B rules requires strong contracts, monitoring, and communication.

To mitigate these challenges, invest in staff education, adopt reliable compliance tools, and maintain open lines of communication with contract pharmacy partners.

What Financial Benefits and Savings Can Covered Entities Expect from the 340B Program?

The direct savings from discounted drug purchases can strengthen a covered entity’s financial position and expand its ability to fund patient services.

How Do 340B Program Savings Impact Safety-Net Hospitals and Clinics?

Savings are often reinvested to:

1. Expand Services: Add or broaden programs that reach underserved populations.
2. Improve Patient Care: Fund quality improvement, care coordination, and patient support.
3. Enhance Infrastructure: Update facilities, technology, and staffing to better serve the community.

Are There Case Studies Demonstrating the Program’s Financial Advantages?

Yes. Case studies show real outcomes — for example, some safety‑net hospitals reported significant revenue increases after implementing 340B strategies, with those funds redirected into patient care initiatives. While results vary by organization, these examples illustrate the program’s potential to support broader clinical and community investments.

What Are the Recent Regulatory Updates and Program Changes for 340B?

Regulatory shifts can affect eligibility, pharmacy arrangements, and compliance obligations. Covered entities should track HRSA guidance and policy changes to adapt operations accordingly.

What Are the Latest HRSA Guidelines and Compliance Updates for 340B?

HRSA has emphasized greater transparency and accountability in recent updates. Covered entities are expected to review internal controls, keep up with reporting requirements, and ensure their practices align with evolving guidance. Regular policy reviews and legal or regulatory consultations can help organizations remain compliant.

How Do 2026 Contract Pharmacy Rules Affect Covered Entities?

New contract pharmacy rules planned for 2026 may introduce stricter documentation and oversight expectations. These changes could affect contract terms, pharmacy management processes, and the compliance workload for covered entities. Preparing now—by auditing current contracts and strengthening pharmacy oversight—will make the transition smoother.

This table highlights core compliance responsibilities covered entities should prioritize to protect program eligibility and minimize risk.

The 340B Program remains a vital tool for organizations serving underserved populations. With clear policies, strong record‑keeping, and proactive oversight, covered entities can use 340B savings to expand access and improve care for the communities they serve.

Frequently Asked Questions

What types of medications are eligible for the 340B Program discounts?

The 340B Program mainly covers outpatient prescription medications—drugs dispensed to patients in outpatient settings. It does not include most inpatient drugs or many over‑the‑counter products, and some specialty medications may be excluded or subject to specific rules. Covered entities should verify eligibility for each product against HRSA guidance and manufacturer policies before purchasing under 340B.

How can covered entities ensure they are compliant with 340B regulations?

Establish a formal compliance program that includes documented policies, routine staff training, accurate transaction records, and internal audits. Keep abreast of HRSA updates, use reliable tracking systems, and consider external compliance reviews when needed. These steps help reduce the chance of errors and demonstrate a commitment to correct program use.

What role do contract pharmacies play in the 340B Program?

Contract pharmacies increase patient access by dispensing 340B drugs on behalf of covered entities when those entities do not operate an in‑house pharmacy. While contract pharmacies expand reach, covered entities retain responsibility for ensuring the pharmacy’s activities comply with 340B rules, so strong agreements and monitoring are essential.

What are the potential risks of non-compliance with the 340B Program?

Non‑compliance can lead to audits, required repayment of discounts, loss of program eligibility, and potential legal or financial penalties. Beyond financial exposure, non‑compliance undermines program integrity and can reduce the resources available to serve vulnerable patients.

How does the 340B Program impact patient care in underserved communities?

By lowering drug acquisition costs, 340B frees up funds that providers can reinvest in services—such as expanded clinic hours, care coordination, transportation assistance, or sliding‑scale programs. These investments can improve access to treatment and support better health outcomes for low‑income and uninsured patients.

What should organizations do if they encounter compliance challenges?

Start with a thorough internal assessment to identify the root causes. Engage compliance specialists or legal counsel if gaps are complex. Implement corrective action plans, invest in staff training and appropriate software tools, and improve communication with contract pharmacies. Prompt, documented remediation is key to resolving issues and reducing future risk.

Conclusion

The 340B Program is an important mechanism that helps covered entities extend care to underserved populations by lowering outpatient drug costs. Understanding eligibility, maintaining robust compliance practices, and planning for policy changes will help organizations protect their 340B benefits and use savings to enhance patient services. Stay informed, document processes carefully, and prioritize transparency to ensure your organization captures the program’s intended value.